Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study.
In the present study, we investigate the outcome of 109 Danish and 123 Swedish patients with nodal PTCL in first complete remission (CR), and examine the impact of imaging-based follow-up (FU) strategies. The patients were selected by the following criteria: (a) newly diagnosed nodal PTCL from 2007 to 2012, (b) age ≥18 years, and (c) CR after CHOP or CHOEP therapy. FU guidelines in Sweden included symptom assessment, clinical examinations and blood tests at 3-4-month intervals for 2 years. FU strategies in Denmark was similar but included routine imaging, usually every 6 months for 2 years. Patients had fully comparable characteristics. Overall survival (OS) estimates for patients in CR were similar for all patients (p = .6) and in PTCL subtypes. In multivariate analysis, country of follow-up had no impact on OS. However, despite continuous CR for ≥2 years, the OS of PTCL remained inferior to a matched general population.
a Department of Clinical Sciences, Oncology and Pathology , Lund University , Lund , Sweden.
Henrik
0000-0003-0728-1549
H
Cederleuf
b Department of Haematology , Aalborg University Hospital , Aalborg , Denmark.|c Department of Clinical Medicine , Aalborg University , Aalborg , Denmark.
Lasse
L
Hjort Jakobsen
a Department of Clinical Sciences, Oncology and Pathology , Lund University , Lund , Sweden.|d Department of Internal Medicine , Kalmar County Hospital , Kalmar , Sweden.
Fredrik
F
Ellin
e Department of Haematology , Rigshospitalet, Copenhagen University Hospital , Copenhagen , Denmark.
Peter
P
de Nully Brown
f Department of Haematology , Odense University Hospital , Odense , Denmark.
Thomas
T
Stauffer Larsen
b Department of Haematology , Aalborg University Hospital , Aalborg , Denmark.|c Department of Clinical Medicine , Aalborg University , Aalborg , Denmark.
Martin
M
Bøgsted
a Department of Clinical Sciences, Oncology and Pathology , Lund University , Lund , Sweden.
Thomas
T
Relander
a Department of Clinical Sciences, Oncology and Pathology , Lund University , Lund , Sweden.
Mats
M
Jerkeman
b Department of Haematology , Aalborg University Hospital , Aalborg , Denmark.|c Department of Clinical Medicine , Aalborg University , Aalborg , Denmark.
Tarec Christoffer
TC
El-Galaly
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003718:Denmark / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D063868:Patient Outcome Assessment; D011159:Population Surveillance; D011878:Radiotherapy; D012074:Remission Induction; D012189:Retrospective Studies; D013548:Sweden / Q000453:epidemiology; D055815:Young Adult
Peripheral T-cell lymphoma; population based; routine imaging